enGene Q1 net loss $10.7M; CEO to resign; $200M PIPE extends cash into 2027

enGene Therapeutics Inc.

2024-Q1 EPS reported $0.46

Net loss $10.7M ($0.46/share) vs $8.6M ($13.29/share) YoY; operating expenses $10.8M vs $4.6M.
Completed $200M oversubscribed PIPE (20M shares at $10, 31% premium); net proceeds $187.5M.
Cash $85.6M as of Jan 31; with PIPE proceeds, expects runway into 2027.
CEO Jason Hanson to resign upon appointment of successor; Board conducting search.
Pivotal Phase 2 LEGEND study for EG-70 in NMIBC on track; interim data mid-2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

enGene Therapeutics Inc. reported first quarter ended January 31, 2024 results: net income net loss attributable to common shareholders was $10.7 million, or $0.46 per share.

Period: first quarter ended January 31, 2024
Net income: net loss attributable to common shareholders was $10.7 million, or $0.46 per share
Result: reported results

Exact text from the filing

enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral intravesical lead product candidate, EG-70, is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced its financial results for the first quarter ended January 31, 2024.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

enGene Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-029396

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.